These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 12380957)

  • 1. Overcoming barriers to erythropoietic therapy. Characteristics of darbepoetin alfa and potential advances in scheduling, dosing, and dose-efficiency.
    Glaspy JA
    Oncology (Williston Park); 2002 Sep; 16(9 Suppl 10):71-7. PubMed ID: 12380957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase III clinical trials with darbepoetin: implications for clinicians.
    Glaspy J
    Best Pract Res Clin Haematol; 2005; 18(3):407-16. PubMed ID: 15792914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Every 3 weeks dosing with darbepoetin alfa: A new paradigm in anaemia management.
    Vansteenkiste JF
    Cancer Treat Rev; 2006; 32 Suppl 2():S11-5. PubMed ID: 16725268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies.
    Hesketh PJ; Arena F; Patel D; Austin M; D'Avirro P; Rossi G; Colowick A; Schwartzberg L; Bertoli LF; Cole JT; Demetri G; Dessypris E; Dobbs T; Eisenberg P; Fleischman R; Hall J; Hoffman PC; Laber DA; Leonard J; Lester EP; McCachren S; McMeekin S; Meza L; Miller DS; Nand S; Oliff I; Paroly W; Pawl L; Perez A; Raftopoulos H; Rigas J; Rowland K; Scullin DC; Tezcan H; Waples J; Ward J; Yee LK
    Cancer; 2004 Feb; 100(4):859-68. PubMed ID: 14770445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer.
    Schwartzberg LS; Yee LK; Senecal FM; Charu V; Tomita D; Wallace J; Rossi G
    Oncologist; 2004; 9(6):696-707. PubMed ID: 15561813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia.
    Cersosimo RJ; Jacobson DR
    Ann Pharmacother; 2006 Jan; 40(1):58-65; quiz 169-70. PubMed ID: 16332942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Darbepoetin alfa for chemotherapy-induced anemia: evolution to extended dosing intervals.
    Vansteenkiste J; Wauters I
    Expert Rev Anticancer Ther; 2007 Oct; 7(10):1347-55. PubMed ID: 17944560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of darbepoetin alfa for the treatment of chemotherapy-induced anaemia.
    Vansteenkiste J; Wauters I
    Expert Opin Pharmacother; 2005 Mar; 6(3):429-40. PubMed ID: 15794734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing the dose and schedule of darbepoetin alfa in patients with chemotherapy-induced anemia.
    Glaspy J
    Oncology (Williston Park); 2006 Jul; 20(8 Suppl 6):29-32. PubMed ID: 16925109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
    Martínez Castelao A; Reyes A; Valdés F; Otero A; López de Novales E; Pallardó L; Tabernero JM; Hernández Jaras J; Lladós F
    Nefrologia; 2003; 23(2):114-24. PubMed ID: 12778875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies.
    Case AS; Rocconi RP; Kilgore LC; Barnes MN
    Gynecol Oncol; 2006 Jun; 101(3):499-502. PubMed ID: 16406064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of darbepoetin alfa administered every two weeks on hemoglobin and quality of life of patients receiving chemotherapy.
    Folloder J
    Oncol Nurs Forum; 2005 Jan; 32(1):81-91. PubMed ID: 15660146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Darbepoetin alfa for the treatment of cancer-related anemia: an update.
    Pirker R
    Expert Rev Anticancer Ther; 2004 Oct; 4(5):735-44. PubMed ID: 15485310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Darbepoetin alfa: an effective treatment with flexible and simplified dosing for anemia in patients with cancer.
    Stevenson JG; Natale JJ
    Pharmacotherapy; 2007 Mar; 27(3):434-46. PubMed ID: 17316154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erythropoietic therapy for the treatment of anemia in patients with cancer: a valuable clinical and economic option.
    Cornes P; Coiffier B; Zambrowski JJ
    Curr Med Res Opin; 2007 Feb; 23(2):357-68. PubMed ID: 17288690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Darbepoetin alfa administered once monthly maintains haemoglobin levels in stable dialysis patients.
    Jadoul M; Vanrenterghem Y; Foret M; Walker R; Gray SJ
    Nephrol Dial Transplant; 2004 Apr; 19(4):898-903. PubMed ID: 15031347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Darbepoetin alfa administered every 2 weeks alleviates anemia in cancer patients receiving chemotherapy.
    Glaspy JA; Tchekmedyian NS
    Oncology (Williston Park); 2002 Oct; 16(10 Suppl 11):23-9. PubMed ID: 12435170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial.
    ; Glaspy J; Vadhan-Raj S; Patel R; Bosserman L; Hu E; Lloyd RE; Boccia RV; Tomita D; Rossi G
    J Clin Oncol; 2006 May; 24(15):2290-7. PubMed ID: 16710026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing the treatment of anemia in cancer patients. The role of a new erythropoietic agent.
    Henry DH
    Oncology (Williston Park); 2002 Oct; 16(10 Suppl 11):9-12. PubMed ID: 12435168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia.
    Boccia R; Malik IA; Raja V; Kahanic S; Liu R; Lillie T; Tomita D; Clowney B; Silberstein P
    Oncologist; 2006 Apr; 11(4):409-17. PubMed ID: 16614237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.